“The CAN10 program continues to advance with important new data generated. These new results give further confirmation that CAN10 can become a safe and highly potent future treatment option for inflammatory diseases with a very high medical need,” said Göran Forsberg, CEO of Cantargia.

CAN10 is one of two clinical projects in the Cantargia pipeline. The CAN10 antibody has been designed for treatment of several autoimmune/inflammatory diseases. The ongoing phase I clinical trial initially investigates increasing levels of CAN10 as single dose administration in healthy subjects followed by studies of multiple dosing in participants with psoriasis. The primary endpoint relates to safety. Details on the trial can be found at https://clinicaltrials.gov/study/NCT06143371.

The first eight dose groups with healthy subjects have now concluded the treatment period. No safety concerns have been observed and the ninth dose group is about to start in accordance with the protocol. The trial is placebo controlled and so far all reviews have been on blinded data. The independent data monitoring committee has now reviewed unblinded data and recommended to continue the study, which means that the next part of the trial, multiple dosing in participants with psoriasis, can start as planned during August 2024. Furthermore, biomarker samples taken during the study show a potent dose dependent blockade of IL1RAP function which was measured as inhibition of IL-36 signaling in immune cells. The effect is pronounced and long-lasting as full inhibition can be observed even a week after a single dose of CAN10.